AU2022355496A1 - Modified interleukin p40 subunit proteins and methods of use thereof - Google Patents

Modified interleukin p40 subunit proteins and methods of use thereof Download PDF

Info

Publication number
AU2022355496A1
AU2022355496A1 AU2022355496A AU2022355496A AU2022355496A1 AU 2022355496 A1 AU2022355496 A1 AU 2022355496A1 AU 2022355496 A AU2022355496 A AU 2022355496A AU 2022355496 A AU2022355496 A AU 2022355496A AU 2022355496 A1 AU2022355496 A1 AU 2022355496A1
Authority
AU
Australia
Prior art keywords
domain
amino acid
modified
fusion protein
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022355496A
Other languages
English (en)
Inventor
Ryan BLACKLER
Thomas SPRETER VON KREUDENSTEIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymeworks BC Inc
Original Assignee
Zymeworks BC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymeworks BC Inc filed Critical Zymeworks BC Inc
Publication of AU2022355496A1 publication Critical patent/AU2022355496A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/10—Design of libraries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022355496A 2021-09-29 2022-09-29 Modified interleukin p40 subunit proteins and methods of use thereof Pending AU2022355496A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163249685P 2021-09-29 2021-09-29
US63/249,685 2021-09-29
PCT/CA2022/051445 WO2023050006A1 (en) 2021-09-29 2022-09-29 Modified interleukin p40 subunit proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2022355496A1 true AU2022355496A1 (en) 2024-05-02

Family

ID=85780291

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022355496A Pending AU2022355496A1 (en) 2021-09-29 2022-09-29 Modified interleukin p40 subunit proteins and methods of use thereof

Country Status (9)

Country Link
US (1) US20240228567A1 (https=)
EP (1) EP4408870A4 (https=)
JP (1) JP2024535925A (https=)
KR (1) KR20240068070A (https=)
CN (1) CN118043343A (https=)
AU (1) AU2022355496A1 (https=)
CA (1) CA3232071A1 (https=)
MX (1) MX2024003940A (https=)
WO (1) WO2023050006A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI880235B (zh) 2017-11-28 2025-04-11 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
WO2025136986A2 (en) 2023-12-18 2025-06-26 Genzyme Corporation Il-12 loss of potency muteins
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019355971B2 (en) * 2018-10-03 2025-05-08 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
JP7773991B2 (ja) * 2020-03-23 2025-11-20 ザイムワークス ビーシー インコーポレイテッド マスクされたｉｌ１２融合タンパク質及びその使用方法

Also Published As

Publication number Publication date
US20240228567A1 (en) 2024-07-11
EP4408870A4 (en) 2025-10-22
JP2024535925A (ja) 2024-10-02
CA3232071A1 (en) 2023-04-06
WO2023050006A1 (en) 2023-04-06
CN118043343A (zh) 2024-05-14
MX2024003940A (es) 2024-04-22
EP4408870A1 (en) 2024-08-07
KR20240068070A (ko) 2024-05-17

Similar Documents

Publication Publication Date Title
US20230122079A1 (en) Masked il12 fusion proteins and methods of use thereof
US20230227584A1 (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
US20240043535A1 (en) IMMUNE ACTIVATING Fc DOMAIN BINDING MOLECULES
CN113677403B (zh) 包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
JP7675083B2 (ja) 新規４－１ｂｂｌ三量体含有抗原結合分子
US20240228567A1 (en) Modified interleukin p40 subunit proteins and methods of use thereof
WO2019086499A1 (en) Novel tnf family ligand trimer-containing antigen binding molecules
EP4565273A2 (en) Masking polypeptides, activatable novel prodrugs and methods of use thereof
WO2025133042A2 (en) Activatable fusion proteins and methods of use
HK40110021A (zh) 经修饰的白细胞介素p40亚基蛋白质及其使用方法
US20250333542A1 (en) Interferon gamma variants and antigen binding molecules comprising these
HK40085919A (en) Masked il12 fusion proteins and methods of use thereof
HK40119034A (zh) 干扰素γ变体以及包含这些变体的抗原结合分子
KR20260030113A (ko) 항체 및 그의 용도
HK40091599A (zh) 免疫活化fc结构域结合分子
HK40075193A (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment